Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …

Immune checkpoint inhibitors (ICIs) have substantially improved the survival of cancer
patients over the past several years. However, only a minority of patients respond to ICI …

Background In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus
ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with …

Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …

High-fidelity DNA replication is critical for the faithful transmission of genetic information to
daughter cells. Following genotoxic stress, specialized DNA damage tolerance pathways …

Over 500 clinical trials are investigating combination radiotherapy and immune checkpoint
blockade (ICB) as cancer treatments; however, the majority of trials have found no positive …

Since the past decades, more lung cancer patients have been experiencing lasting benefits
from immunotherapy. It is imperative to accurately and intelligently select appropriate …